Literature DB >> 25642338

Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?

Abraham J Wu1, Karyn A Goodman1.   

Abstract

Definitive chemoradiation (CRT) is a well-established treatment for esophageal cancer, but disease recurrence is common and many patients do not achieve initial remission with CRT alone. Predictors of outcome with CRT are needed to guide prognosis and further treatment decisions, in particular the need for post-CRT surgery. We review the role of baseline clinical factors, such as histology and tumor bulk, in predicting response to CRT. Post-CRT assessments, particularly PET imaging, may provide further information about the likelihood of complete response and survival, but the predictive power of clinical assessments remains limited. Emerging research on biomarkers holds promise for more tailored and accurate prediction of outcome with definitive CRT.

Entities:  

Keywords:  Esophageal cancer; chemoradiation (CRT); radiotherapy; response prediction

Year:  2015        PMID: 25642338      PMCID: PMC4294820          DOI: 10.3978/j.issn.2078-6891.2014.099

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  52 in total

1.  Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.

Authors:  Stephen G Maher; Dermot T McDowell; Ben C Collins; Cian Muldoon; William M Gallagher; John V Reynolds
Journal:  Ann Surg       Date:  2011-11       Impact factor: 12.969

2.  Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Authors:  Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

3.  Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Authors:  David H Ilson; Bruce D Minsky; Geoffrey Y Ku; Valerie Rusch; Nabil Rizk; Manish Shah; David P Kelsen; Marinela Capanu; Laura Tang; Jenny Campbell; Manjit Bains
Journal:  Cancer       Date:  2011-10-11       Impact factor: 6.860

4.  Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.

Authors:  J Wen; H Yang; M Z Liu; K J Luo; H Liu; Y Hu; X Zhang; R C Lai; T Lin; H Y Wang; J H Fu
Journal:  Ann Oncol       Date:  2014-06-06       Impact factor: 32.976

5.  MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.

Authors:  Michael Augustine Ko; Guan Zehong; Carl Virtanen; Maha Guindi; Thomas K Waddell; Shaf Keshavjee; Gail E Darling
Journal:  Ann Thorac Surg       Date:  2012-08-29       Impact factor: 4.330

6.  Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.

Authors:  Akihiro Suzuki; Lianchun Xiao; Yuki Hayashi; Homer A Macapinlac; James Welsh; Steven H Lin; Jeffrey H Lee; Manoop S Bhutani; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

7.  A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.

Authors:  L E Gaspar; K Winter; W I Kocha; L R Coia; A Herskovic; M Graham
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

8.  ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.

Authors:  J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry
Journal:  Mol Oncol       Date:  2013-10-28       Impact factor: 6.603

9.  Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.

Authors:  Yin-Kai Chao; Chen-Kan Tseng; Yu-Wen Wen; Yun-Hen Liu; Yung-Liang Wan; Cheng-Tung Chiu; Wen-Cheng Chang; Hsien-Kun Chang
Journal:  Ann Surg Oncol       Date:  2013-04-13       Impact factor: 5.344

10.  Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Authors:  Nabil P Rizk; Laura Tang; Prasad S Adusumilli; Manjit S Bains; Timothy J Akhurst; David Ilson; Karyn Goodman; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

View more
  6 in total

1.  Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Authors:  Fatemeh G Amlashi; Xuemei Wang; Raquel E Davila; Dipen M Maru; Manoop S Bhutani; Jeffrey H Lee; Brian R Weston; Dilsa Mizrak Kaya; Maria Vassilakopoulou; Kazuto Harada; Mariela A Blum Murphy; David C Rice; Wayne L Hofstetter; Marta Davila; Quynh-Nhu Nguyen; Jaffer A Ajani
Journal:  Oncology       Date:  2018-05-29       Impact factor: 2.935

Review 2.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

3.  Significance of intratreatment tumor volume change during chemoradiotherapy for potentially resectable thoracic esophageal squamous cell carcinoma.

Authors:  Duojie Li; Qun Zhang; Yan Yang; Hongmei Yin; Chaomang Zhu; Xianming Li
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

4.  Intratreatment Tumor Volume Change During Definitive Chemoradiotherapy is Predictive for Treatment Outcome of Patients with Esophageal Carcinoma.

Authors:  Ruihong Huang; Hong Guo; Jianzhou Chen; Tiantian Zhai; Junwei Chen; Kun Lin; Zhijian Chen; Derui Li; Chuangzhen Chen
Journal:  Cancer Manag Res       Date:  2020-08-18       Impact factor: 3.989

5.  Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma.

Authors:  Yong Ji; Xiao-Bo Wu; Jing-Yu Chen; Bin Hu; Qian-Kun Zhu; Xing-Feng Zhu; Min-Feng Zheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.

Authors:  Assuero Giorgetti; Giovanni Pallabazzer; Andrea Ripoli; Biagio Solito; Dario Genovesi; Monica Lencioni; Maria Grazia Fabrini; Simone D'Imporzano; Laura Pieraccini; Paolo Marzullo; Stefano Santi
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.